Warning
Teva Pharmaceuticals USA Recalls Clonidine Transdermal System
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0474-2026Drug / Pharmaceutical
Teva Pharmaceuticals USA Recalls Clonidine Transdermal System
Teva Pharmaceuticals USA, Inc · Class II — Moderate Risk
Product Description
Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx only, Manufactured by: Actavis Laboratories UT Inc., Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc, Parsippany, NJ, NDC 0591-3510-04 carton, NDC 0591-3510-54 pouch
Reason for Recall
CGMP Deviations: use of an unapproved raw material
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Within U.S
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Teva Pharmaceuticals USA, Inc has recalled a pharmaceutical product that the FDA classified as Class II affecting 113,943 Cartons. The recall was initiated on March 19, 2026. CGMP Deviations: use of an unapproved raw material. It was distributed nationwide. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medication Defects and Teva Pharmaceuticals USA recalls.